Market Research Logo

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2016

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2016’, provides an overview of the Hospital Acquired Pneumonia (HAP) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP)
  • The report reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hospital Acquired Pneumonia (HAP) therapeutics and enlists all their major and minor projects
  • The report assesses Hospital Acquired Pneumonia (HAP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP)
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Pneumonia (HAP)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Hospital Acquired Pneumonia (HAP) Overview
Therapeutics Development
Pipeline Products for Hospital Acquired Pneumonia (HAP) - Overview
Pipeline Products for Hospital Acquired Pneumonia (HAP) - Comparative Analysis
Hospital Acquired Pneumonia (HAP) - Therapeutics under Development by Companies
Hospital Acquired Pneumonia (HAP) - Therapeutics under Investigation by Universities/Institutes
Hospital Acquired Pneumonia (HAP) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Hospital Acquired Pneumonia (HAP) - Products under Development by Companies
Hospital Acquired Pneumonia (HAP) - Products under Investigation by Universities/Institutes
Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development
Achaogen Inc.
Adenium Biotech ApS
Aridis Pharmaceuticals LLC
AstraZeneca Plc
Bayer AG
Cardeas Pharma Corp.
MedImmune, LLC
Meiji Seika Pharma Co., Ltd.
Melinta Therapeutics, Inc
Merck & Co., Inc.
Motif Bio Plc
Nabriva Therapeutics AG
Savara Inc.
Sealife PHARMA GMBH
Shionogi & Co., Ltd.
Tetraphase Pharmaceuticals Inc.
Wockhardt Limited
Zavante Therapeutics, Inc.
Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(amikacin sulfate + fosfomycin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(avibactam + ceftazidime) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(ceftolozane sulfate + tazobactam sodium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(cilastatin sodium + imipenem + relebactam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(Pseudomonas + ventilator associated pneumonia) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AA-139 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aerucin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amikacin sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arbekacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cefepime + zidebactam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
delafloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eravacycline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosfomycin tromethamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iclaprim mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lefamulin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-3902 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-4893 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nu-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAC-I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Panaecin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
panobacumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plazomicin sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Qn-2251 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-649266 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0905 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tedizolid phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tosatoxumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vancomycin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WCK-2349 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WCK-771 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hospital Acquired Pneumonia (HAP) - Dormant Projects
Hospital Acquired Pneumonia (HAP) - Discontinued Products
Hospital Acquired Pneumonia (HAP) - Product Development Milestones
Featured News & Press Releases
Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
Jun 20, 2016: Results of Phase 2 Study of Merck's Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe
Feb 24, 2016: Aridis Pharmaceuticals Expands Patent Portfolio for Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets
Jan 07, 2016: Aridis Pharmaceuticals Reports Positive Phase 1 Clinical Results for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia
Dec 15, 2015: Iclaprim Clinical Trial Supplies Manufactured
Oct 13, 2015: Motif Bio Announces Results of Two Posters on Iclaprim at ID Week 2015
Sep 29, 2015: Motif Announces Presentation of Two Posters on Iclaprim at ID Week 2015
Jun 30, 2015: Aridis Pharmaceuticals Receives FDA Fast Track Designation for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia
Jan 08, 2015: Achaogen Announces Plazomicin Granted QIDP Designation by FDA
Oct 03, 2013: Tetraphase to Present New Data at IDWeek on Eravacycline’s Potential Activity in Treating Serious Respiratory Infections
Sep 06, 2013: Trius Therapeutics to Present Data From Antibiotics Development Programs at ICAAC 2013
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2016
Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016
Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc., H2 2016
Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS, H2 2016
Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals LLC, H2 2016
Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H2 2016
Hospital Acquired Pneumonia (HAP) - Pipeline by Bayer AG, H2 2016
Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp., H2 2016
Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune, LLC, H2 2016
Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co., Ltd., H2 2016
Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics, Inc, H2 2016
Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co., Inc., H2 2016
Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H2 2016
Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG, H2 2016
Hospital Acquired Pneumonia (HAP) - Pipeline by Savara Inc., H2 2016
Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH, H2 2016
Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co., Ltd., H2 2016
Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2016
Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Limited, H2 2016
Hospital Acquired Pneumonia (HAP) - Pipeline by Zavante Therapeutics, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Hospital Acquired Pneumonia (HAP) - Dormant Projects, H2 2016
Hospital Acquired Pneumonia (HAP) - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2016
Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report